Akebia Therapeutics Inc (AKBA) USD0.00001

Sell:$2.35Buy:$2.38$0.10 (4.39%)

Prices delayed by at least 15 minutes
Sell:$2.35
Buy:$2.38
Change:$0.10 (4.39%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.35
Buy:$2.38
Change:$0.10 (4.39%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Key people

John P. Butler
President, Chief Executive Officer, Director
Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Steven K. Burke
Senior Vice President - Research and Development, Chief Medical Officer
Nicholas Grund
Senior Vice President, Chief Commercial Officer
Adrian Adams
Independent Chairman of the Board
Ronald E. Frieson
Independent Director
Steven C. Gilman
Independent Director
Michael W. Rogers
Independent Director
Cynthia Smith
Independent Director
Click to see more

Key facts

  • EPIC
    AKBA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00972D1054
  • Market cap
    $539.67m
  • Employees
    181
  • Shares in issue
    249.85m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.